Screener
Collegium Pharmaceutical, Inc. COLL Symproic and other — Cost
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Collegium Pharmaceutical, Inc. in its filing.
Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsGross.
The source filing: Collegium Pharmaceutical, Inc.’s 10-K, filed February 26, 2026.
- Filed
- Feb 26, 2026, 7:34 AM EST
- Fiscal year
- FY2025
- Accession
- 0001628280-26-011992
| Line item | As of December 31, 2025 / Cost | As of December 31, 2025 / Accumulated Amortization | As of December 31, 2025 / Carrying Amount | As of December 31, 2024 / Cost | As of December 31, 2024 / Accumulated Amortization | As of December 31, 2024 / Carrying Amount |
|---|---|---|---|---|---|---|
| Jornay PM | $635,000 | $(111,072) | $523,928 | $635,000 | $(27,242) | $607,758 |
| Belbuca | 360,000 | (284,607) | 75,393 | 360,000 | (209,214) | 150,786 |
| Nucynta Products (1) | 521,170 | (493,478) | 27,692 | 521,170 | (438,094) | 83,076 |
| Symproic | 70,000 | (27,503) | 42,497 | 70,000 | (20,218) | 49,782 |
| Total intangibles | $1,586,170 | $(916,660) | $669,510 | $1,586,170 | $(694,768) | $891,402 |
Item 16. Form 10-K Summary
FAQ
- What is Collegium Pharmaceutical, Inc.'s symproic and other — cost?
- Collegium Pharmaceutical, Inc. (COLL) reported symproic and other — cost of $70M in Q4 2025.
- What does symproic and other — cost mean?
- Reflects the total direct costs associated with producing, distributing, and supporting the Symproic product line. Monitoring this metric helps assess the direct profitability and cost-efficiency of this specific business segment.
Ask your AI about Collegium Pharmaceutical, Inc.'s symproic and other — cost.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude